Semaglutide vs. Tirzepatide vs. Retatrutide: Which GLP-1 Is Right for You?

Two years ago, the GLP-1 conversation was basically Ozempic, Ozempic, Ozempic. Today, there are three generations of these medications in play, with strikingly different mechanisms and results - and a fourth wave on the horizon. If you’re deciding between them, considering a switch, or wondering whether to wait for what’s coming next, here’s the plain-English comparison.

Meet the three

Semaglutide (brand names Ozempic, Wegovy, Rybelsus) is the original of this class for weight loss. It’s a single agonist (it mimics one gut hormone, GLP-1) which slows gastric emptying, suppresses appetite, and improves blood sugar control. FDA-approved for type 2 diabetes (2017) and obesity (Wegovy, 2021). Average weight loss in trials: about 15%.

Tirzepatide (brand names Mounjaro, Zepbound) is a dual agonist - it mimics GLP-1 and a second gut hormone, GIP (glucose-dependent insulinotropic polypeptide). The GIP activation improves insulin secretion, enhances fat metabolism, and in some patients appears to reduce GLP-1-related nausea. FDA-approved for diabetes (2022) and obesity (Zepbound, 2023). Average weight loss in trials: about 20–22%, and in head-to-head comparisons with semaglutide, tirzepatide has produced roughly 40% more weight loss.

Retatrutide is the triple agonist - GLP-1, GIP, and glucagon. Yes, glucagon, which traditionally raises blood sugar. But at the doses used in retatrutide, glucagon receptor activation appears to shift metabolism toward fat burning and actually increases energy expenditure through thermogenesis. In a Phase 2 trial, participants lost an average of 24% of body weight at 48 weeks; the Phase 3 TRIUMPH-4 trial reported 28.7% weight loss at the highest dose. It is not yet FDA-approved. Expected timeline: late 2027 to 2028.

The numbers, side by side

A quick note on cross-trial comparisons: these percentages come from separate trials with different populations and durations, so they aren’t perfectly apples-to-apples. But head-to-head data does exist for semaglutide vs. tirzepatide, and tirzepatide wins consistently. Retatrutide’s edge over tirzepatide is still being formally confirmed in Phase 3, but Phase 2 data is striking.

The side effect picture

All three share a similar GI-heavy side effect profile: nausea, vomiting, diarrhea, constipation. The severity and frequency generally correlate with how many receptors the drug activates and how quickly you titrate up. Some nuances worth knowing:

Semaglutide has the longest clinical track record, the most cardiovascular outcome data (the SELECT trial followed more than 17,000 patients), and generally the most established tolerability profile.

Tirzepatide has a reputation among many clinicians for being somewhat better tolerated than semaglutide, possibly because the GIP component mitigates some of the nausea GLP-1 causes.

Retatrutide shows higher discontinuation rates in trials (around 18%) and a higher incidence of dysesthesia (unusual skin sensations) likely related to the glucagon component. More weight loss, but a harder drug for some bodies to stay on.

Who each one tends to be best for

Semaglutide is often the right starting point for patients who want the longest-studied option, have moderate weight loss goals (10–15%), have cardiovascular disease (where semaglutide has specific outcome data), or want the option of an oral form (Rybelsus, and the newer Wegovy pill).

Tirzepatide is currently the best-evidence choice for most patients seeking maximum weight loss from an FDA-approved medication. It’s also the common next step for people who plateaued on semaglutide.

Retatrutide is being positioned as the future option for patients with the highest BMIs who need maximum weight loss, patients who have inadequately responded to tirzepatide, and potentially patients with significant hepatic fat (since the glucagon component reduced liver fat by about 50% in trials). It is not available yet outside of clinical trials, and anyone selling it online right now is selling something unregulated.

What women specifically should think about

One early and interesting finding about retatrutide: Phase 2 data suggested participants lost a smaller proportion of lean mass compared to semaglutide or tirzepatide users, likely because the glucagon component preserves muscle while burning fat. If confirmed in Phase 3, this would be genuinely meaningful for women, who already face disproportionate muscle loss risk on GLP-1s.

But - and this is the part nobody writing about these drugs wants to emphasize - no medication in this class preserves muscle on its own. Whichever drug you’re on, muscle preservation is still going to be driven by what you eat and how you move. Protein intake (1.2–1.6 g/kg of goal body weight), strength training two to three times a week, and adequate sleep matter far more than the brand of pen in your fridge. A well-formulated high-protein nutrition shake designed for GLP-1 users works the same way on all three medications, because the math of muscle preservation is the same regardless of whether you’re on a single, dual, or triple agonist.

Should you wait for retatrutide?

For most women: no. Assuming FDA approval arrives in late 2027 or early 2028, waiting for retatrutide means roughly two more years of delayed treatment, and losing weight with a currently approved medication is almost certainly better than not losing weight while waiting for a marginally more powerful one.

Tirzepatide available now will produce substantial weight loss for most people. If you plateau or hit a wall, retatrutide is a realistic next step when it arrives. Think of it as a staircase, not a decision tree.

The bottom line

Semaglutide is the tested original. Tirzepatide is the currently best-performing approved option. Retatrutide is the likely future, probably best for patients who need more than the current medications can offer. All three work on roughly the same biological highway — they just cover different lanes of it.

The medication matters. What you do around it matters more.

This article is for informational and educational purposes only and is not medical advice. Please consult your healthcare provider about which medication is appropriate for you. Retatrutide is an investigational medication not yet approved by the FDA, and should only be accessed through legitimate clinical trials.

Sources

1. Better Med Spa, “Semaglutide vs Tirzepatide vs Retatrutide: 2026 Chicago Guide.” https://www.bettermedspa.com/blog/posts/semaglutide-tirzepatide-retatrutide-chicago

2. CompoundReview, “Semaglutide vs Tirzepatide vs Retatrutide (2026): Full Comparison.” https://compoundreview.com/versus/semaglutide-vs-tirzepatide-vs-retatrutide

3. GLP3 Planner, “Retatrutide vs Semaglutide: Weight Loss, Results & Which Is Better (2026).” https://glp3planner.com/resources/retatrutide-vs-semaglutide

4. CompoundReview — note on cross-trial comparison caveats. https://compoundreview.com/versus/semaglutide-vs-tirzepatide-vs-retatrutide

5. Voy, “Retatrutide vs Tirzepatide vs Semaglutide comparison.” https://www.joinvoy.com/blog/retatrutide-vs-tirzepatide-vs-semaglutide

6. Reta Weight Loss, “Retatrutide 2026: 28.7% Weight Loss, 8 Trials, Q4 NDA Filing” — discontinuation and dysesthesia rates. https://www.retaweightloss.com/article/complete-retatrutide-guide-2026-phase-3-trials-timeline-whats-next

7. TheNNT, “Efficacy of Tirzepatide, Retatrutide, and Semaglutide for Weight Loss in Obese Individuals Without Diabetes,” 2025. https://thennt.com/nnt/efficacy-of-tirzepatide-retatrutide-and-semaglutide-for-weight-loss-in-obese-individuals-without-diabetes/

8. GLP3 Planner — retatrutide Phase 2 data on lean mass preservation. https://glp3planner.com/resources/retatrutide-vs-semaglutide

9. Reta Weight Loss — recommendation not to wait if you qualify for current options. https://www.retaweightloss.com/article/retatrutide-vs-tirzepatide-vs-semaglutide-2026-comparison-with-phase-3-data